Most London patients go private to access weight loss drugs
The majority of patients in London taking weight loss medications are doing so privately, with slow rollouts meaning only a …
Post
-
-
GSK’s RSV jab secures FDA label expansion to larger adult population
GSK has secured a label expansion for its respiratory syncytial virus (RSV) vaccine, Arexvy, from the US Food and Drug …
-
Widespread US shift from prescription to OTC lies in pharma’s hands
In an interview from February 2026, commissioner of the US Food and Drug Administration (FDA), Marty Makary, said that “everything …
-
Biophytis and LynxKite expand alliance to boost AI-driven drug discovery
Biophytis has expanded its existing partnership with LynxKite Technologies to accelerate AI-driven longevity drug discovery, beginning with the MAS Receptor …
-
Novartis wins FDA approval for Cosentyx to treat paediatric HS patients
Novartis has received the US Food and Drug Administration (FDA) approval for Cosentyx (secukinumab) to treat paediatric patients aged 12 years …
-
Parkinson’s research reaches “pivotal” stage, but barriers remain
Preclinical and clinical research focused on Parkinson’s disease has reached a “pivotal point”, but funding barriers and outdated clinical trial …
-
Nine ways to ensure a reliable technology transfer
While these transfers are a normal part of business, navigating them requires a strategic approach to ensure smooth and efficient …
-
WHO directs antibiotic development to priority pathogens
The World Health Organization (WHO) has outlined desired antibacterial characteristics for three priority infections as part of a move to …
-
PRISM BioLab partners with Receptor.AI for molecule discovery
PRISM BioLab has formed a collaboration with Receptor.AI to integrate AI and physics-guided technologies in the discovery of orally available …
-
PsiQuantum and National Cancer Center Japan partner on quantum computing
PsiQuantum and the National Cancer Center Japan have entered a collaborative research agreement to drive advancements in utility-scale quantum computing …
-
Vima banks $100m in Series A to progress Parkinson’s drug
Massachusetts-based biotech Vima Therapeutics has extended its Series A financing by $40m to advance its investigational Parkinson’s and dystonia pill, …
-
Eli Lilly finds impurity in compounded tirzepatide
Eli Lilly has warned of high levels of an impurity in certain compounded versions of its blockbuster glucagon-like peptide-1 receptor …
-
Wegovy portfolio growth shifts to the pill as injectable sales forecast to plateau
In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation of …
-
Bavarian Nordic and SII sign agreement for chikungunya vaccine production
Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract …
-
Curatis and Neupharma sign development agreement for corticorelin in Japan
Switzerland-based Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain oedema …
